My name is Dr. Matthew Barth and I’m a pediatric hematologist and oncologist at Roswell Park. I care for patients with all types of pediatric hematology and oncology diagnoses; however, I primarily focus on pediatric leukemia and lymphoma patients with a specialty in non-Hodgkin lymphoma.
My clinical and laboratory research and expertise center on targeted therapies for lymphomas. This research has also given me a strong background in genomic medicine programs, which I use to coordinate genomic testing for our pediatric patients leading to a targeted care plan.
I have a research lab where I perform experiments aimed at understanding mechanisms of action of new agents for treating pediatric lymphomas. My research has been supported through a Buswell Fellowship, St. Baldrick’s Foundation Scholar Award, and the Hyundai Hope on Wheels Foundation. I also participate in the development of clinical trials testing new targeted therapies in children with non-Hodgkin lymphoma.
Along with my clinical and research roles, I’m also an Assistant Professor in Pediatrics at the Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, and an attending physician in the Division of Hematology/Oncology in Pediatrics at the Oishei Children’s Hospital. In this role, I oversee the training of medical students, residents and fellows training in pediatrics and pediatric hematology and oncology.
I earned my medical degree from the State University of New York Upstate Medical University in Syracuse, NY. I completed both my residency in pediatrics and my fellowship in pediatric hematology/oncology at the University at Buffalo in Buffalo, NY. I am board certified in both general pediatrics and pediatric hematology and oncology.
I’m a member of a number of professional societies, including:
- The American Society of Clinical Oncology
- American Society of Hematology
- American Society of Pediatric Hematology/Oncology
- The Children’s Oncology Group
- International Society of Paediatric Oncology
My research articles have been published in various medical journals and I have presented my research at many national and international oncology conferences, as well as presenting to institutions about the latest treatments, therapies and medicines in pediatric hematology and oncology.
I’m privileged to have received these awards and honors:
- International Society of Pediatric Oncology: Young Investigator Award (2016).
- 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma; Outstanding Translational Biology Research (2015).
- National Institutes of Health: Loan Repayment Program Award (2012-2017).
- 11th International Conference on Malignant Lymphoma: Travel Award (2011).
- Roswell Park Comprehensive Cancer Center: Best Basic Science Fellow Research Report (2011).
- University of Buffalo Jacobs School of Medicine and Biomedical Sciences: Thomas F. Frawley, MD Residency Research Fellowship (2011).
- University of Buffalo Jacobs School of Medicine and Biomedical Sciences: Henry C. and Bertha H. Buswell Fellowship (2011-2014).
I serve on the Children’s Oncology Group’s Non-Hodgkin Lymphoma Committee, and have participated in the Children’s Oncology Group Young Investigator Mentoring Program. I also review manuscripts for the Journal of Leukemia and Lymphoma, PLoS One, Journal of Pediatrics, Pediatric Hematology and Oncology and Pediatric Blood and Cancer.
- Czuczman NM, Barth MJ, Gu J, Neppalli V, Mavis C, Frys SE, Hu Q, Liu S, Klener P, Vockova P, Czuczman MS, Hernandez-Ilizaliturri FJ. Pevonedistat, a NEDD8 Activating Enzyme Inhibitor, is active in Mantle Cell Lymphoma and Enhances Rituximab Activity in vivo. Blood. 2016 Mar 3;127(9):1128-37. doi: 10.1182/blood-2015-04-640920.
- Barth MJ, Mavis C, Czuczman MS and Hernandez-Ilizaliturri FJ. Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in pre-clinical models of mantle cell lymphoma. Clin Cancer Res. 2015 May 11. pii: clincanres.0056.2015.
- Barth MJ, Chu Y, Hanley PJ, Cairo MS. Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. 2016 Apr 7. doi: 10.1111/bjh.14078.
- Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, Harrison L, Sanger W, Geyer MB, Giulino-Roth L, Cairo MS. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children’s Oncology Group (COG) report. Br J Haematol. 2013 Jun 27. doi: 10.1111/bjh.12434.
- Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS. Ofatumumab Demonstrates Activity Against Rituximab Sensitive and Resistant Cell Lines, Lymphoma Xenografts and Primary Tumor Cells From Patients With B-cell Lymphoma. Br J Haematol. 2012 Feb;156(4):490-8. doi: 10.1111/j.1365-2141.2011.08966.x
- Alrazzak M, Beaupin L, Kinyon P and Barth MJ. The incidence of hypersensitivity reactions to pegylated asparaginase in children with acute lymphoblastic leukemia: a city-wide experience. J Pediatr Hematol Oncol. 2016 Jan;38(1):e16-20. doi: 10.1097/MPH.0000000000000465.